Ebselen, a Seleno-Organic Compound, Inhibits Leukocyte Aggregation and Reduces the Plasma Leukotriene B4 Level in Humans and Rats
Recent evidence suggests that intravascular activation of leukocytes may be implicated in the pathogenesis of inflammation, postischemic injury and atherothrombotic diseases (Harlan 1985). Thus, the prevention of leukocyte activation represents a possible target for therapeutic intervention in these diseases. Ebselen [2-phenyl-1,2-benzisoselenazol-3(2H)-one] is a seleno-organic compound which catalyzes the degradation of hydroperoxides (Müller et al. 1984), converts leukotriene B4 (LTB4) into its biologically inactive 6-trans isomer (Kuhl et al. 1986) in the presence of glutathione, and inhibits arachidonate 5-lipoxygenase (Safayhi et al. 1985) and superoxide anion production (Ichikawa et al. 1987) in leukocytes. We have, therefore, studied the effect of ebselen on leukocyte activation in rats and humans after oral administration. This was done by assessing its inhibition of LTB4-induced whole blood aggregation ex vivo. In addition, we have investigated possible effects of ebselen on platelet aggregation and the concentrations of LTB4, thromboxane B (TXB2) and 6-keto-prostaglandin F1α a (6-keto-PGF1 α) in plasma after oral administration.
KeywordsPlatelet Aggregation Superoxide Anion Production Leukocyte Activation Leukocyte Aggregation Atherothrombotic Disease
Unable to display preview. Download preview PDF.